$STE

Zangerle John Adam sold $297K of STE

Zangerle John Adam (Sr. VP, Gen Counsel, and Sec.) sold 1,419 shares of STERIS plc (STE) at $209.28 ($0.30M total) on 2026-06-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Zangerle John Adam
Published Jun 16, 2026, 8:31 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 16, 2026, 8:36 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$STE
Neutral
high confidence
Mentioned
$STE
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STENeutralLow
01

Why it matters

The newest fact is the specific sale size, price, and that it was executed under a pre-arranged 10b5-1 plan; no other company-specific developments are provided.

02

Market read

This provides incremental transparency on insider activity but lacks fundamental catalysts, so trading impact is likely limited.

03

What to watch

Traders may overreact to insider sales; without changes in guidance, contracts, or litigation, the incremental information is mostly sentiment-level.

Relevance 3/10Novelty 6/10Timing: Filed 2026-06-16; transaction dated 2026-06-15.

Background

The article is a SEC Form 4 insider transaction disclosure for STERIS plc.

Company-level read

Ticker impact

$STENeutralHigh confidence
Context

STERIS disclosed an officer’s open-market sale of 1,419 shares at $209.28 under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move from this filing alone.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan and no accompanying fundamental or regulatory catalyst.

Market effects

No sector read-across; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because it’s a pre-arranged 10b5-1 plan, the sale may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • STERIS plc

    Subject of the Form 4 insider transaction disclosure.

  • Zangerle John Adam

    Sr. VP, General Counsel, and Secretary; reported an open-market sale.

Related articles

$STEMed

STERIS plc (STE): Results of Operations and Financial Condition

STERIS plc (STE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ste6302026ex991.htm EX-99.1 Document Exhibit 99.1 STERIS Announces Financial Results for Fiscal 2027 First Quarter • Fiscal 2027 first quarter revenue increased 7%; constant currency organic revenue growth was 6% • Fiscal 2027 first quarter as reported diluted EPS incre

$STEMedAI 8/10

Are Wall Street Analysts Predicting STERIS Stock Will Climb or Sink?

STERIS plc (STE) has lagged the market, falling 11.2% over the past year versus a 27.9% S&P 500 gain, and is down 14.6% in 2026 YTD. After Q4 results on May 11 (revenue $1.6B, +7.3% YoY; adjusted EPS $2.83, +3.3%), analysts expect FY2027 EPS of $11.18 (+9.9%). Consensus is “Moderate Buy” (5 “Strong Buy,” 3 “Hold”); KeyBanc cut its target to $269.